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http://www.globalizationandhealth.com/content/10/1/11RESEARCH Open AccessDiabetes in Algeria and challenges for health
policy: a literature review of prevalence, cost,
management and outcomes of diabetes and its
complications
Larbi Lamri1, Erofile Gripiotis2 and Alessandra Ferrario2*Abstract
Background: Diabetes has become an increasingly prevalent and severe public health issue in Algeria. This article
investigates the prevalence, the cost and the management of this disease. Its first objective is to better understand
the burden (both from an epidemiological and economic perspective) and management of diabetes. The second
objective is to understand the health policy strategy adopted by Algeria in order to respond to the disease.
Methods: We conducted a literature review of prevalence, costs, management and outcomes of diabetes and its
complications. This was complemented by data compilations and results of expert consultations.
Results: The epidemiology of diabetes is continually evolving and is becoming more problematic. The national
evidence suggests that the prevalence of diabetes in Algeria has increased from 6.8% in 1990 to 12.29% in 2005,
but is quite higher among certain groups and areas of the country. This disease affects all population groups,
especially 35–70 year olds, who constitute a large segment of the working population. There are very few estimates
of the cost of diabetes. These include a 1998 study on the total cost of type 1 diabetes (USD 11.6 million, which,
inflated to 2013 value, totals to USD 16.6 million), a study on the cost of complications in 2010 (at 2013 value,
ranging from USD 141 for first-year treatment of peripheral vascular disease to USD 30,441 for first-year cost of renal
transplantation) and the 2013 IDF estimates of total cost of type 1 and type 2 diabetes (USD 513 million).
Conclusions: As the prevalence of diabetes continues to increase, the financial burden will increasingly weigh
heavily on social security resources and the government budget. Future priorities must focus on empowering
general practitioners in treating type 2 diabetes, improving screening of diabetes and its complications, tackling the
growing obesity epidemic, strengthening health information systems and implementing the national diabetes
prevention and control plan.
Keywords: Diabetes, Costs, Algeria, Prevalence, Diabetes managementBackground
Similar to much of the developing world, Algeria is
currently undergoing an epidemiological transition. While
mal- and undernutrition and infectious diseases used to
be the main causes of poor health, today there is a higher
proportion of chronic, non-communicable diseases (NCDs),
including diabetes mellitus, cardiovascular disease, cancer* Correspondence: a.ferrario@lse.ac.uk
2London School of Economics and Political Science, Houghton Street,
London WC2A 2AE, UK
Full list of author information is available at the end of the article
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reproduction in any medium, provided the orand respiratory diseases. According to estimates for Algeria
from the World Health Organization (WHO), NCDs
accounted for 63% of all deaths in 2010 [1]. By compari-
son, a smaller proportion of overall mortality (29%) that
year was attributed to communicable diseases, maternal,
perinatal and nutritional conditions (injuries represented
the remaining 8%) [1].
Type 2 diabetes, once considered a disease of indus-
trialised nations, is now becoming increasingly preva-
lent in Algeria and other emerging countries, ranking as
the fourth most prevalent non-communicable disease [2].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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a double burden of disease, which has significant impli-
cations not only for population health but also in socio-
economic contexts.
Assessment of the prevalence, complications, costs and
outcomes of diabetes in Algeria has been rather limited by
insufficient data and projections on the significance of
the disease from a public health perspective. A literature
review on the prevalence of diabetes mellitus was pub-
lished in 2008 [3]. However, evidence on the burden and
management of type 1 and type 2 diabetes in Algeria is
fragmentary. This study aims to address this gap by con-
ducting a comprehensive literature review of available
data sources on the burden and management of diabetes
(including the prevalence of both type 1 and type 2,
complications, costs, health outcomes and policies de-
veloped in response to the disease) and using this as a
basis to formulate evidence-based policy recommendations
for Algeria.
Overview of Algerian health care system
Algeria is the largest country in Africa and is estimated
to have a population of around 38 million inhabitants
[4]. Approximately 70% of the population lives in the
coastal region, north of the minority who live in the
Sahara region mainly concentrated in oases, while 1.5
million belong to nomadic communities; almost 30% of
Algerians are under 15 years of age [2].
The Algerian health system has both public and private
health sectors. The public health sector is accessible and
free-of-charge for all Algerian citizens; it is dually financed
by government contributions and social insurance. There
are 12.1 physicians and 19.5 nurses/midwives, respectively,
per 10,000 population [5]. The number of health care
facilities varies from one area of the country to another,
depending on the size of the local population.
In 2011, Algeria’s total expenditure on health per capita
was USD 354 at purchasing-power parity, which repre-
sented 3.9% of gross domestic product [6]. In that same
year, general government and private expenditures on
health represented 80.8% and 19.2% of total health expend-
iture, respectively [6]. Of general government expenditure
on health, 32.4% was constituted of social security funds
while 94.7% of private expenditure on health was out-of-
pocket spending [6]. There is a national medical insurance
scheme run by the Caisse Nationale des Assurances
Sociales des Travailleurs Salariés (CNAS) that covers 90%
of the entire population [7]. Public health insurance is
available for salaried employees and independent workers
such as traders.
Medicines are reimbursed at 80% of the reference price;
medical procedures (consultations, examinations and tests)
are also reimbursed at 80%. All patients who are employed
in the formal sector and have chronic diseases (includingdiabetes) are reimbursed 100% of the costs of care and
medicines (patients receive medicines free-of-charge as
they are covered by health insurers which pay pharmacies
a fixed price). Low-income formal sector workers (i.e. with
health insurance) are identified by the Algerian Ministry
of National Solidarity and Family and local authorities
(districts and sub-districts). Individuals belonging to
this patient group are provided a card which grants
them access to free medication and care; the ministry
and local authorities pay for their health care costs.
Methods
This study is based primarily on a comprehensive literature
review, internet research and consultations with rele-
vant experts.
The literature review was conducted in November
2013 using English as well as French keywords. The
following search engines were accessed: PubMed, Web
of Science, Scopus, Google Scholar and Google.
English keyword searches in PubMed used the following
keywords: Algeria OR Algerian AND diabetes OR diabetic
OR neuropathy OR retinopathy OR nephropathy OR
“renal replacement” OR “chronic kidney” OR “diabetic
foot” OR “foot ulcer” AND prevalence OR expenditure
OR expenses OR cost OR “economic burden”.
French keyword searches in PubMed used the following
key words: Algérie OR algérien AND diabète OR diabé-
tique OR neuropathie OR rétinopathie OR néphropathie
OR “l'insuffisance rénale chronique” OR “pied diabétique”
OR “mal perforant plantaire” AND “prevalence” OR
“dépenses” OR “coût” OR “fardeau économique”.
In Web of Science, Scopus, Google Scholar and Google,
varying combinations of the key words listed above were
used in searches.
We did not put any time limits or language restric-
tions on our search. Articles that were retrieved through
the literature review which did not present relevant evi-
dence of the prevalence, costs, complications, treatment or
outcomes of diabetes in Algeria were not retained for ana-
lysis. Studies that used both primary and secondary data
were included. Where such information was available, we
distinguished between type 1 and type 2 diabetes.
In addition to articles procured through the aforemen-
tioned search engines, relevant material known by the
authors was consulted; this includes data from national,
regional and local health surveys and diabetes studies. Data
from the Algerian Ministry of Health, the International
Diabetes Federation (IDF) and WHO were also con-
sulted, along with government reports pertaining to na-
tional health policy and diabetes programmes. Finally,
additional articles were identified from the references in
the retrieved literature.
Given the limited reliable data available for diabetes
and the absence of a data collection system at the national
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heads of specialist endocrinology-diabetology and internal
medicine departments and directors of the Ministry of
Health concerned with NCDs, as well as representatives
of academic institutions and NGOs. Their input could
overcome the shortcomings of non-aggregated data at
the national level.
To update costs to 2013 United States dollars (USD), we
used the Consumer Price Index (CPI) inflation calculator
tool provided by the U.S. Department of Labor [8].
Results
In PubMed, English keyword searches yielded 65 search
results while French keyword searches did not yield any
search results when using all of the keywords (some results
were returned using various combinations of the keywords).
In Web of Science and Scopus, English keyword searches
yielded 23 search results and 46 search results, respectively,
while French keyword searches yielded one search result
and six search results, respectively. The majority of these
papers were excluded through title screening and abstract
screening because they did not meet inclusion criteria
or were repeated results.
Ultimately, three papers were retained from PubMed,
four papers from Web of Science and six papers from
Scopus (Table 1). Through Google Scholar and Google,
an additional three peer-reviewed papers were identi-
fied. Two more papers were identified through reference
searching in other papers. The remaining references are
comprised of grey literature, such as government reports
and data from WHO and IDF, along with pertinent sources
known by the authors.
Data sources
A limited number of data sources on the burden, complica-
tions, costs and outcomes of diabetes in Algeria were iden-
tified. These include national and regional surveys, regional
diabetes registers, a local register of renal replacement
therapy and other studies.
National data
Major national studies that were identified include four
studies on prevalence, two studies on costs and one study
on complications, treatment and outcomes.Table 1 Literature
Area of diabetes
management
Number of
references retrieved
References
Prevalence 8 [9-12,16-19]
Costs 3 [14,15,26]
Complications 2 [13,21]
Treatment 2 [13,20]
Outcomes 1 [13] National Health Survey: Conducted in 1990 by the
National Institute of Public Health, the National
Health Survey was a broad public health survey
which involved a sample of 12,041 households
covering all age groups. Diabetes patients were
identified through self-reporting and population
survey. There was no distinction between type 1 and
type 2 diabetes [9].
 WHO STEPWise Approach Study: This study, using
the “WHO STEPWise approach to surveillance”
(STEPS), was conducted in 2003 under the auspices
of the Ministry of Health and the direction of the
National Diabetes Committee. It covered a sample
of 4,050 adults aged 25 to 64 years in two pilot areas
with the aims of assessing the frequency and
distribution of risk factors for NCDs and the
prevalence of diabetes, arterial hypertension cancer
and chronic respiratory conditions [10].
 MICS 3 UNICEF: This study was conducted in 2006
on a sample of 29,008 women (aged 15 to 40 years)
and children (under 5 years old) [11].
 TAHINA (Transition And Health Impact in North
Africa) Study: Conducted in 2005 by the National
Institute of Public Health, this national health survey
used a representative sample of 4,818 adults aged 35
to 70 years. It is a comprehensive research project
on Algeria’s epidemiological transition with the aims
of estimating the level of morbidity (including
prevalence and incidence), health care consumption
and frequency of risk factors pertaining to chronic
diseases among adults aged 35 to 70 years. Diabetes
patients were identified through blood glucose
testing. Only type 2 diabetes was studied [12].
 DiabCare Algeria: This is a prospective, multicentre
transversal study on diabetes in Algeria that was
funded by Novo Nordisk and conducted in 2008 by
clinical researchers at six university hospital centres
in the Central, East and West regions of the
country. It assessed glycaemic control, risk factors,
diabetes complications and therapeutic regimens
based on an evaluation of 977 patients with both
type 1 and type 2 diabetes [13].
 Priorités de santé en Algérie (Health Priorities in
Algeria): Cost data in this 1998 study were collected
from three university hospitals in Algiers; fixed costs
(infrastructure, depreciation, personnel) were
considered separately from variable costs
(drugs, radiological examinations, laboratory tests).
Information on resource utilisation was provided by
a panel of physicians [14].
 Direct Medical Management Costs of Diabetes-Related
Complications in Algeria: Costs in this 2012 study were
collected from official sources identified using local
resources. They were divided into six categories based
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cardiovascular complications, renal complications,
acute events, eye-disease and neuropathy/foot ulcers)
and presented as first-year costs and costs in
subsequent years following an event in 2011 USD [15].
Regional and local data
Four major regional studies and three regional registers
on prevalence, in addition to one local register on treat-
ment, were identified.
 Region “West” study: Conducted in 2007 in
Tlemcen (Western Algeria) based on WHO criteria
which used a sample of 7,656 subjects (2,799 men
and 4,857 women) over 20 years of age [16].
 Region “East” survey: Conducted in 2001 in Sétif
(eastern Algeria) on a sample of 1,457 subjects aged
30 to 64 years [17].
 Region “Centre” survey: Conducted in 2010 and
involved 1,036 children under 15 years of age. By
gender, the sample was comprised of 47.5% boys and
52.5% girls and the age category distribution was
12% (0–4 years), 34% (5–9 years) and 54%
(10–14 years) [18].
 Region “South” (Sahara) survey: Conducted in 2002
of the “Touareg” population of the Algerian Sahara
with a sample of inhabitants whose age and sex were
not specified [19].
 Diabetes registers: There are three functioning and
up-to-date regional registers for type 1 diabetes in
children under 15 years of age. These registers are
filled in by medical specialists, who also analyse and
manage the data. The first register was created in
Oran (Western region) in 1980, the second one was
created in Constantine (Eastern region) in 2000
and the third register was created in Algiers
(Central region) in 2010 – all by the National Institute
of Public Health (which is also responsible for
maintaining the registers). The Ministry of Health
recently announced that record-keeping would be
extended to 48 districts in the country and that a
gestational diabetes register would be created. In
addition to basic demographic information of the
patient, these registers contain information on
health indicators and treatment of diabetes
(including incidence, mortality, date of diagnosis,
quality of care and a range of tests for HBA1c,
lipids, hypertension and weight), as well as
complications arising from and/or linked with the
disease. However, these registers do not contain
data on the direct or indirect costs associated with
diabetes (i.e. medicines, tests, etc.).
 Renal replacement therapy register: A register was
created in 2009 in the city of Constantine andgradually improved over time [20]. The register
collects basic patient information such as age, sex,
blood group and place of care in addition to
disability, co-morbidities and cause of death for all
patients undergoing dialysis in Constantine.
Other studies
Additional smaller studies on complications [21]; risk
factors [22,23]; consanguinity [24]; and fasting during
Ramadan were identified [25].
Prevalence and distribution of type 2 diabetes
While the national studies sampled different groups and
regions and employed different methodologies, evidence
from them suggests that the prevalence of diabetes in
Algeria has increased from 6.8% in 1990 to 12.29% in
2005 (Table 2) [9,12]. In 2005, diabetes was the second
most common chronic disease (8.78%) among 35-to-70-
year-olds, preceded only by hypertension (16.23%) [12]. The
national prevalence of diabetes in Algeria in 2013, ac-
cording to the IDF, is estimated at 6.63% (the comparative
prevalence is 7.47%) [26].
Similar observations regarding the prevalence and distri-
bution of diabetes in the national studies were reflected in
the regional studies. The 2007 Tlemcen study reported
the prevalence of type 1 and type 2 diabetes at 14.2% in
western Algeria [16]. The prevalence of type 2 diabetes
(initially non-insulin-dependent diabetes mellitus) was 10.5%
and type 1 diabetes (insulin-dependent diabetes mellitus)
was 3.7% [16]. Diabetes prevalence was higher in urban
(15.3%) than rural (12.9%) areas and higher among men
(20.4%) than women (10.7%) [16]. The 2001 Setif study re-
ported type 2 diabetes prevalence at 8.2%, increasing with
age, but with no significant difference according to sex or
urban (7.3%) / rural distribution in eastern Algeria (9.7%);
half of the diabetes cases in this study had been previously
undiagnosed [17].
The TAHINA study also found that the increase in
morbidity as a result of NCDs such as diabetes, hyperten-
sion, chronic respiratory illnesses, chronic renal failure
and cancer is associated with lifestyle changes in relation
to food, obesity, physical activity and psychological stress.
It was found that being overweight was a risk factor
for type 2 diabetes and was observed in 55.9% of those
surveyed. Furthermore, obesity was more common in
women (66.5%), those aged 45 to 59 years (62.7%), those
living in urban areas (58.8%) and those residing in the
Central Highlands (57.8%) [12]. The Tlemcen study con-
firmed the link between obesity and diabetes prevalence,
finding that 56.7% of all men and more than half of all
women in urban areas were obese on the basis of body
mass index (BMI) [16].
Two studies on risk factors in two areas in western
Algeria further confirm the link between type 2 diabetes
Table 2 Prevalence
Prevalence of DM
Estimate Study year Sampling frame and sample Study design Diagnostic test and diagnostic criteria Reference
DM2: 2.1% (1992), 8.7% (1994), 7.3% (2006) 2008 Multiple sampling frames and samples Multiple study designs Multiple diagnostic test and criteria [3]
Overall: 6.8% 1990 Sampling frame: N/A Cross-sectional Diagnostic test: Self-reporting,
population survey
[9]
Sample: 12,041 households covering all
age groups
Diagnostic criteria: N/A
Overall: 8.9% 2003 Sampling frame: two pilot villages Cross-sectional Diagnostic test: Fasting blood glucose [10]
Sample: 4,050 adults aged 25 to 64 years Diagnostic criteria: American Diabetes
Association (ADA): The person is treated for
diabetes or has a glycaemia level >1.26 g/l
Overall: 2.1% November-
December 2005
Sampling frame: Four regions: Central,
South, East, West
Cross-sectional Diagnostic test: Self-reporting,
population survey
[11]
Males: 1.9%
Females: 2.3%
Peak age group was 60+ (12.5%),
followed by 35–59 (4.1%) and 25–34 (0.4%)
Sample: 25,919 females aged 15 to 49 years
and 3,089 children under 5 years of age
Diagnostic criteria: N/A
More prevalent in urban areas (2.6%)
than in rural areas (1.5%)
More prevalent among the richest quintile
(3.5%) than among the poorest quintile (1%)
Overall: 12.29% June 2005 Sampling frame: Three regions: Tell, High Cross-sectional Diagnostic test: Glucose testing [12]
Males: 11.93%
Females: 12.54% Plateaus, South (Sahara) Diagnostic criteria: N/A
Peak age group was 60–64 (22.37%), followed
by 65–70 (22.05%) and 55–59 (13.70%)
Sample: 4,818 adults aged 35 to 70
More prevalent in urban areas (13.81%)
than in rural areas (9.62%)
More prevalent in the High Plateaus
(13.27%) than in the Tell (12.26%) or South
(Sahara) (8.52%)
Overall: 14.2% 2007 Sampling frame: Tlemcen
(in western Algeria)
Cross-sectional Diagnostic test: Fasting blood sample [16]
Males: 20.4%
Females: 10.7% Sample: 7,656 adults (2,799 males, 4,857
females) over 20 years of age
Diagnostic criteria: WHO (1985)
DM1: 3.7%
DM2: 10.5%
More prevalent in urban areas (15.3%)
than in rural (12.9%) areas
DM2: 8.2% 2001 Sampling frame: Setif (in eastern Algeria) Cross-sectional Diagnostic test: Oral glucose tolerance test [17]
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Table 2 Prevalence (Continued)
7.3% urban vs. 9.7% rural Sample: 1, 457 subjects aged 30 to 64 years Diagnostic criteria: WHO
Overall prevalence: 13.8% 2010 Sampling frame: Central Algeria Cross-sectional Diagnostic test: N/A [18]
Sample: 1,036 children under 15 years of age
(47.5% boys and 52.5% girls; age category
distribution–12% (0–4 years), 34% (5–9 years)
and 54% (10–14 years)
Diagnostic criteria: N/A
DM2: 1.3% 2002 Sampling frame: Adrar (in southern Algeria) Cross-sectional Diagnostic test: N/A [19]
Sample: 1,000 subjects Diagnostic criteria: N/A
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ducted in an urban community of Tlemcen observed
significant prevalence rates of diabetes and obesity
(16.1% and 19.2%, respectively) [22]. A study in Maghnia,
conducted in 2008–2009, revealed that obesity, physical
inactivity and irregular food intake were among the most
important environmental risk factors associated with
type 2 diabetes [23]. This study also noted that people
with a family history of diabetes were at higher risk for
developing the disease.
Additionally, the TAHINA study observed a low con-
sumption of fruits, vegetables and fish (even in coastal areas)
along with a high intake of processed foods, fats, sugars and
grains. For physical activity, activities of low and moderate
intensity were practised by 60.5% and 8.35%, respectively, of
those surveyed [12].
In a 2009 case–control study of gestational diabetes, it
was found that risk factors for the disease include family
history of type 2 diabetes, being overweight and a his-
tory of polyhydramnios and/or macrosomia in previous
pregnancies [27]. This study demonstrated a signifi-
cantly higher number of Caesarean sections and pre-
mature births among pregnant women diagnosed with
gestational diabetes compared to those without diabetes
(type 1, type 2 or gestational). Gestational diabetes is asso-
ciated with increased infant and maternal morbidity and
mortality in the short term, and there is a significant
risk of the mother developing diabetes (typically type 2)
in the long term. Additionally, children born to mothers
with gestational diabetes frequently are obese and have
impaired glucose tolerance [27].
Prevalence and incidence of type 1 diabetes in children
There are three regional registers collecting data on the
incidence, prevalence and treatment of type 1 diabetes
in children under 15 years of age. According to the data
from Oran and Constantine, the incidence in 2000 was
12 cases per 100,000 people, representing approximately
1,146 new cases per year for the whole country based on
census figures from 2008 [28].
The register for Algiers (Central region) reported the
prevalence of type 1 diabetes to be 13% in 2010. When
broken down by age group, type 1 diabetes prevalence is:
4.4% of children under 5 years of age, 15.4% of 5–9-year-
olds and 23.5% of 10–14-year-olds. The incidence in 2011
was 22.8 cases per 100,000 people, representing 171 new
cases for the Central region alone and increasing among
younger people, including infants. Family history is a
contributing factor in half of these cases.
Diabetes complications
While there are limited available data and no baseline
studies on diabetes complications, we were able to iden-
tify two relevant studies [13,21] (Table 3). Additionally,we consulted with an array of Algerian public health of-
ficials and medical specialists.
The 2008 DiabCare Algeria study was conducted on 977
patients with both type 1 and type 2 diabetes. The ma-
jority of patients (86.1%) had type 2 diabetes, were young
(mean age: 48.5 years), overweight (mean BMI: 27.7 kg/m2)
and with a disease duration of 10 years. The 2009 diabetic
retinopathy study was conducted on 1,152 diabetes patients
(type 1 and type 2 diabetes) 15 years of age or older in
Algiers province [13].
According to the DiabCare study, the most common
complication was diabetic neuropathy (diagnosed in over
44% of patients), followed by diabetic retinopathy (a third
of patients). One in five patients had a micro-albuminuria
and a little over a third of patients had macroproteinuria.
End-stage renal disease was found in 0.52% of type 2
diabetes patients. Stroke was found to be more frequent
in type 2 diabetes (2.6% vs 1.5% in type 1 diabetes) [13].
The diabetic retinopathy study found that this complica-
tion had a prevalence of 48.6% (type 1 and type 2 diabetes)
and that it increased with disease duration [21]. According
to expert opinion, monitoring of eye problems related
to diabetes is very limited due to a lack of adequate oph-
thalmic services.
In consulting with NCD specialists at the Ministry of
Health, we found that diabetic neuropathy and damage
to the lower limbs occurs in 50% of people with diabetes.
Additionally, 25% of cases of patients with arthritis of
the lower limbs have been found to be linked to dia-
betes, with a quarter of such cases requiring amputation;
the number of these amputations per year was estimated
to be between 800 and 1,300.
According to cardiologists who were consulted, as well
as past Algerian newspaper articles published on World
Diabetes Day, it is estimated that 50% of diabetes patients
have cardiovascular complications. These occur two to
three times more often and with greater severity in
people with type 2 diabetes when compared to people
without the disease.
Consultations with nephrologists revealed that 14%
of kidney failure is due to diabetes and that in 2011,
approximately 2,000 people with diabetes had to undergo
dialysis (this figure was relatively low due to the fact that
only around 5% of the population is 65 and over [4]).
The incidence of renal failure is approximately 50 to
100 new cases per year. Given the current growth rate
of diabetes, the projection of new cases is expected to
increase.
Costs of diabetes and complications
There are limited reliable data on the costs of diabetes
and its complications, and the currently available data
are often fragmented or combined with other types of
medical costs. As a result, only two relevant studies were
Table 3 Complications
Estimate Study year Sample frame and sample Study design Diagnostic test and diagnostic criteria Reference
Diabetic retinopathy 2008 Sample frame: Three Clinical screening Diagnostic test: Blood samples [13]
34.5% (N = 977, n = 300) regions: Central, East, West Diagnostic Criteria: ADA
DM1: 36.2% (n = 46) Sample: 977 diabetes patients with
DM1 (n = 136) and DM2 (n = 841)
DM2: 34.2% (n = 254)
Diabetic neuropathy
44.7% (N = 977, n = 433)
DM1: 35.8% (n = 48)
DM2: 46.2% (n = 385)
End-stage renal disease
.5% (N = 977, n = 5)
DM1: 0% (n = 0)
DM2: .6% (n = 5)
Diabetic retinopathy Dec 2008-Jun 2009 Sample frame: Algiers province Cross-sectional Diagnostic test: N/A [21]
DMT1/2: 48.6% ± 2.9% Diagnostic Criteria: Alfediam criteria
(Association de langue française pour l'étude
du diabète et des maladies métaboliques)Males: 49.6%
Females: 50.4% Sample:
1,152 diabetes patients; 15 years of age
or older with DM1, DM2 insulin-treated
(IT) and DM2 non-insulin-treated (NIT)
diabetes. Divided into three groups
(n = 384) based on disease duration
(less than 5 years, between 5–10 years,
longer than 10 years).
DM1: 47.9% ± 7.0%
DM2 (IT and NIT.): 48.7% ± 5.2%
DMT2 (IT): 70.6% ±4.6%
DMT2 (NIT): 35.2% ± 3.8%
Proliferative diabetic retinopathy: 10.9% ± 1.8%
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the IDF (Table 4).
The 1998 study was conducted by local researchers
using the methodology of the World Bank and incorporat-
ing the disability adjusted life years concept [14]. Cost data
in this study were primarily collected from three university
hospitals in Algiers. This study determined that the treat-
ment of type 1 diabetes in Algeria cost on average USD 351
per year (60% of this was on drug expenditure). Based on
an estimated prevalence of 7.76% in the age affected group
(which amounted to 33,184 cases), the total cost came to
USD 11.6 million.
The 2010 study observed that the highest first-year costs
were for renal complication treatments: renal transplant-
ation (USD 28,422), continuous ambulatory peritoneal
dialysis (USD 3,901) and haemodialysis (USD 3,742) [15].
Cardiovascular complications also incurred high annual
costs and ranged from USD 865 for first-year treatment of
myocardial infarction to USD 132 for first-year treatment
of peripheral vascular disease. Additional first-year costs
of treating cardiovascular complications were identified
for stroke (USD 282), congestive heart failure (USD 244)
and angina (USD 395). Also, the cost of an amputation
procedure was USD 533, excluding the cost of prosthesis
(USD 618), with a follow-up cost of USD 22. The cost of a
cataract operation was USD 123, while the cost of a
laser eye procedure was USD 48.
The methodology used by the IDF to derive estimates
was based on information on country-by-country estimatesTable 4 Costs
Source of cost* Original amount (US
Average treatment costs per year per patient 351 [1998]
Average total treatment costs per year 11.6 million [1998]
Renal transplantation 28,422 [2010]
Continuous ambulatory peritoneal dialysis 3,901 [2010]
Haemodialysis 3,742 [2010]
Myocardial infraction 865 [2010]
Peripheral vascular disease 132 [2010]
Stroke 282 [2010]
Congestive heart failure 244 [2010]
Angina 395 [2010]
Amputation procedure 533 [2010]
Prosthesis 618 [2010]
Follow-up post- amputation procedure 22 [2010]
Cataract operation 123 [2010]
Laser eye procedure 48 [2010]
Health expenditure for diabetes in 2013 512,682,393***
Health expenditure for diabetes in 2035 813,889,950***
*First-year treatment costs unless otherwise indicated.
**Costs updated to 2013 USD using U.S. Department of Labor’s Consumer Price Index
***Authors’ calculation based on IDF data.of diabetes prevalence by age and sex, population size
by age and sex, total healthcare expenditures by age
and sex and the ratio of expenditures per person with
diabetes to expenditures per person without diabetes,
matched for age and sex [29].
According to the IDF, spending on diabetes per patient
was USD 313 in 2013, representing a total spending of
nearly USD 513 million for the Algerian health care
system [26].
Screening and prevention of diabetes
Some screening has been implemented systematically in
all diabetes treatment centres such as day hospitals, but
it is less frequent in polyclinics. Screening is targeted to
high-risk groups, defined as patients age 35 and older
with a family history of the disease, obese patients and
women who have delivered babies with a high birth
weight. Regarding gestational diabetes, screening is not
currently performed as part of standard antenatal care,
so early detection is absent both for women in general
and women at risk [27].
The Ministry of Health has developed disease preven-
tion programmes based on WHO’s integrated approach;
these have focused on the identification and monitoring
of diabetes risk factors.
There are also many diabetes associations at the national
and regional levels which play an active role in disease
prevention. Scientific societies such as the Algerian Society
of Diabetology continue to raise awareness about theD) [Year] 2013 US Dollar (USD) amount** Reference
503 [14]
16.6 million
30,441 [15]
4,178
4,008
926
141
302
261
423
571
662
24
132
51
– [26]
–
(CPI) inflation calculator tool: http://www.bls.gov/data/inflation_calculator.htm.
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improved diets and increased activity levels. In addition to
that, pharmaceutical companies are also involved in
diabetes screening and prevention activities.
Treatment
In treating diabetes, the medical community abides by
international standards established by WHO. Additionally,
the guide to best practices for diabetes prevention that was
developed by the National Diabetes Committee has served
as a reference tool.
During the 12 months preceding the 2008 DiabCare
study, 18% of patients had received education on treatment
regimens and only 56.6% of type 1 and 63.1% of type 2 dia-
betes patients benefited from the use of dietary guidelines
[13]. HBA1c test was performed on average three times per
year. Therapeutically, 80.1% of type 2 diabetes patients were
on an oral anti-diabetic (OAD), 26.3% were on OAD and
insulin and 19.6% were on insulin only. Biguanides were
the OAD class most frequently prescribed (63.5%), followed
by sulfonylureas (44.0%), meglitinides (glinides) (6.7%)
and α-glucosidase inhibitors (1.4%). The type 2 diabetes
patients received an average insulin dose of 42.2 ± 25.2
U/day (0.6 ± 0.3 units/kg/d) with an average number of
injections of 2.0 ± 0.9 U/j (58.1% of them used insulin
pens). The type 1 diabetes patients received an average
insulin dose of 58.2 ± 22.5 U/day (0.9 ± 0.3 units/kg/d)
with average of three injections per day (half of them
used insulin pens).
Patients with diabetes are treated and rehabilitated in
public hospitals that specialise in internal medicine
and endocrinology, public diabetes treatment centres
and private specialist clinics and medical offices. Because
public health care is free, most patients with diabetes
receive their treatment from public hospitals. To have
routine medical tests performed, patients can visit public
hospitals as well as private medical testing laboratories;
expenses are reimbursed by social insurance. Lower
limb prostheses for insured patients are covered by social
security under specialised services, while non-insured
patients must pay directly for this equipment (however,
national NGOs generally cover these costs for them).
Dialysis is available in both public and private centres
(the former is free-of-charge, the latter is paid for by
social security and/or health insurance).
There are approximately 20 specialised hospitals that
treat only diabetes in Algeria, playing an important role
in the prevention and treatment of this disease. In these
facilities, diabetes patients have access to high-quality,
multidisciplinary therapeutic treatment, including con-
sultations, investigations and screening of complica-
tions, provided by endocrinologists, diabetologists and
internists. Additional services include: dietary advice
to promote eating healthy and nutritionally balancedmeals; training in the use of insulin and the glucose
monitor; psychological support; eye and cardiologic exams
and diabetic foot care; and social assistance for obtaining
medicines. Diabetes patients are regularly monitored by
their doctor on an average bi-monthly basis.
The Algerian drug market is adequately supplied
with insulin, oral medications and test strips. A signifi-
cant portion of insulin has been locally produced and
will be further developed through local investment.
Many oral medications such as novoformine are pro-
duced locally in generic form, and imports supplement
domestic production.
Access to medicines is generally considered satisfactory.
The insured and their beneficiaries, along with welfare re-
cipients in possession of social cards, obtain their medica-
tions free-of-charge in pharmacies that have established
agreements with the two main health insurance organisa-
tions. Additionally, all chronically ill patients employed in
the formal sector, including people with diabetes, have an
electronic card that allows them to obtain prescribed drugs
free-of-charge in pharmacies. Test strips are procured in
the same manner as prescription drugs and patients are re-
imbursed for 100% of the cost of test strips; the price is
fixed by their doctor according to the daily number of test
strips, added up to the monthly number of test strip boxes
that a patient is expected to use. Glucose meters, however,
are not reimbursed (though NGOs provide these at no cost
to those who cannot afford them). Additionally, patients
are reimbursed for 100% of the cost of insulin in all its
forms (injection pens, pumps, etc.).
According to a local register of renal replacement therapy
from the city of Constantine, conventional haemodialysis is
the most frequently used method for renal replacement
therapy, comprising 90% of cases (this figure includes
diabetes as well as non-diabetes patients) [20]. Renal
transplantation, as a form of renal replacement therapy,
does not appear to be widespread, largely because of the
unacceptability of cadaveric donors (due to ethical ques-
tions raised by Islamic law) which limits organ supply to
living donors.
Health outcomes
Data on health outcomes for diabetes patients are limited,
but a few sources provide some insight into disease control
and mortality.
In the DiabCare Algeria study (2008), glycaemic control
was poor with an average HbA1c of 8.52%, and more than
one third of the patients studied had a HbA1c level higher
than 9% [13]. Only 18.7% of diabetes patients reached
HbA1c <7%.
Diabetes also contributes to mortality. In Algeria in 2010,
diabetes accounted for 4% of all deaths [1]. According
to the IDF, 14,431 deaths have been attributed to diabetes
in 2013 [26].
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When examining a particular disease in a specific coun-
try context, it is important to also consider cultural
issues which may affect the burden and management of
the disease. Regarding diabetes in Algeria, religious fasting
(during Ramadan) and consanguineous marriages are two
important issues to consider.
Algeria is 99% Muslim, and as in all majority-Muslim
countries, the holy month of Ramadan is one of the most
important holidays for the country’s inhabitants [4].
From dawn to sunset during Ramadan, followers of
Islam fast by entirely abstaining from eating, drinking
water (or any other liquid), taking oral medications and
smoking. Once they break the fast at sunset, people con-
sume one to three meals, with some people snacking until
dawn; the foods consumed between sunset and dawn tend
to be high in sugar and fat. While Ramadan allows exemp-
tions from fasting for high-risk and ill individuals, includ-
ing people with diabetes, the majority of them still insist
on fasting [25]. During the holy month, in fact, severe
hypoglycaemia is the main cause of hospitalisations.
Diabetes patients in Algeria face additional complications
such as ketoacidosis, dehydration, orthostatic hypotension
and thrombosis when fasting for Ramadan [25].
The practice of consanguineous marriages has not been
extensively studied in relation to the prevalence of diabetes,
despite the fact that in Algeria (as in many other North
African as well as Middle Eastern countries), consanguin-
eous marriages (unions between closely-related individuals)
are not uncommon. According to a 2007 Algerian study
by the National Foundation for Health Promotion and
Research Development, one Algerian in four is married
to a cousin [30]. To establish the profile of people at
high risk of type 2 diabetes, a study of 1,561 subjects
was conducted in 2010 across five regions and cities in
Algeria using a logistic model [24]. In the overall sample,
the rate of consanguinity was found to be 48%. This study
concluded that consanguineous marriages, along with
hereditary predisposition and obesity, were significant
risk factors for the disease [24].
Health policy and diabetes programmes
The government of Algeria is concerned about the con-
comitant changes that have resulted from the growth of
NCDs and the increased social demand for quality care.
In 2003, the Minister of Health at the time emphasised
that only primary and secondary prevention through
education and the promotion of healthy lifestyles, screening
and early treatment of cases offer effective and relatively
inexpensive means of significantly reducing the burden
of NCDs [31].
National health policy, in an effort to combat the growing
diabetes epidemic, has aimed to re-direct resources to-
wards correcting regional imbalances in the supply ofcare (i.e. hospital infrastructure and health personnel)
and the management of NCDs by building specialised
hospitals and by training specialists and skilled workers.
It also aims to preserve the free care provided by the
government for low-income individuals and to streamline
the entire health care system.
The draft national plan against diabetes for 2011–2020
was adopted by Algeria’s Parliament in 2012, but the legisla-
tive presidential decrees have not yet been developed and
signed. This plan is mainly characterised by the fact that
it is integrated into the global WHO approach to NCDs
(which is general and based on several global studies)
that is founded on prevention at the primary (targeting
risk factors), secondary (screening) and tertiary (prevention
of complications) levels. The plan differs from the previous
strategy in its multidisciplinary action that incorporates
a number of ministerial departments and emphasises
awareness, training, prevention and integrated control
against risk factors in order to reverse the upward trend
of the disease. The allocation of a special budget solely
to the fight against diabetes is expected to help address
regional inequalities in terms of providing and ensuring
equity of care for patients.
Policies addressing the rise in obesity that is a major
contributing factor to the increased prevalence of type 2
diabetes appear to be limited. There are occasional tele-
vised advertisements that call attention to the negative
health effects of cheap, processed food. However, taxes
are not levied on such “junk” food and there is no regu-
lation on food advertising to children.
Discussion
Our study was limited by the lack of reliable and extensive
data. There do not appear to be many recent national or re-
gional studies on diabetes mellitus in Algeria that have been
published or made publicly available. This may be partially
attributed to the absence of an integrated information
system and the focus, until recently, on infectious diseases
(though the public health context is changing). Additionally,
the databases from which we collected various statistics
and costs cite the methodological challenge of basing their
estimates on insufficient national data; this is especially
pertinent to developing countries such as Algeria.
This study has found that the epidemiology of diabetes
is continually evolving. According to forecasts of the
Ministry of Health, there were 4.4 million people with
diabetes in Algeria in 2012, and this estimate is projected
to increase to 4.8 million by the year 2015. (The Ministry
of Health’s estimates are based primarily on numbers
of known diabetes patients, but the numbers of those
undiagnosed would certainly increase these figures).
Diabetes now affects all population groups in Algeria,
with an estimated national prevalence rate for those ages
20 to 79 of 6.63%, resulting in a 1.7 million patients [26].
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ing population whose households could be severely
affected economically, to the point of patients being
forced to make difficult choices between basic necessities
(food, shelter, etc.) and health care.
Although 90% of the Algerian population is covered by
a social insurance scheme, there are nearly one million
workers (such as artisans) in the informal sector whose
income goes unreported and untaxed and who, in turn,
do not receive government health benefits [7]. When
additional family members and their dependents are
taken into account, the number of those without any
coverage reaches approximately 3.5 million, according to
the Algerian Ministry of Labour, Employment and Social
Security. Based on an approximate diabetes prevalence
of 10% (as an average of studies discussed earlier), it is
estimated that approximately 350,000 patients are not
specifically covered for payment of diabetes treatment.
The estimated one million people working in the informal
sector earn an income and procure their medication and
care from the private sector; these are non-reimbursed
expenses, which patients must pay for out of pocket.
The geographical features of Algeria reflect the organisa-
tional and demographic challenges that are currently facing
health care providers and planners, particularly regarding
the risk of chronic disease. Regional disparities appear in
the context of specialised care. There is a general shortage
of endocrinologists, diabetologists and internists across
regions. The Ministry of Health has sought to fill this
gap by training general practitioners in poorer areas to
enable them to treat and educate patients diagnosed
with diabetes. Because there are not enough diabetolog-
ists, the Ministry of Health provides additional training
for GPs working in remote areas to treat diabetes. The
training of general practitioners is an ongoing mission
to first detect diabetes (particularly type 2) in people,
and then to dispense advice on diet and exercise to those
who are diagnosed; more intense treatment regimens are
provided in specialised hospitals.
Deficiencies found in the care of diabetes patients
are most acute when there are complications. Hospital
departments providing specialised treatments (i.e. foot
care, cardiology, nephrology, ophthalmology) are not
always able to accommodate these additional patients.
Additionally, despite broadening efforts, screening policy is
marred by deficiencies in its organisation, standardisation
and communication. There are no routine screening
procedures in place in doctors’ offices or private consulting
services for major hospitals.
Diabetes poses a significant burden on the economy.
According to forecasts of the Algerian Ministry of Health,
national health expenditure has more than doubled since
2001. The amount spent on diabetes is expected to rise
to as high as 816 million by 2035 [15]. Costs related totreatment for complications of diabetes are expected to add
to the financial burden of social insurance programmes
in Algeria. Since type 2 diabetes affects a significant
proportion of the population aged 35 to 60 years, and
people are now living longer than they did a few genera-
tions ago (life expectancy at birth is 71 and 74 years of age
for males and females, respectively), there clearly are nega-
tive implications for limited public resources, particularly in
regard to social security [1].
Absence from work due to illness (absenteeism) and
premature death considerably reduce the national income,
while early retirement for workers and sick pensions for in-
valids further compound the burden on financial resources
allocated to social security. Furthermore, households
can be doubly burdened because the disease increases
the risk of job losses and care-related expenses, which
can prove to be unbearably costly for low income or in-
formal sector workers.
This predicament is further exacerbated in an emerging
country like Algeria, which is more likely to face serious
financial instability that can potentially interfere with
economic growth and development efforts.
Conclusion
According to the available published literature and
majority of the diabetologists consulted, the shift from
the traditional life style to a more Westernised one is
the major explanatory factor behind the rapid progres-
sion of diabetes mellitus, particularly type 2, in Algeria.
Indeed, residents in urban and even rural areas have
become more sedentary, exercise less and have replaced
their consumption of foods rich in fibre, such as vege-
tables and fruits, with cheaply-priced products that are
readily available in the market place and are high in sat-
urated fats and refined sugar. This has led to a significant
increase in obesity.
While access to health care services, at least for in-
sured patients, is fairly good, health outcomes appear to
be quite poor. Screening and prevention initiatives are
expanding, but they remain poorly organised and poorly
coordinated; given that these represent the most effect-
ive approach to reducing the complications of the dis-
ease and its serious socio-economic consequences, this
must be addressed.
Since diabetes is now a widespread public health con-
cern, the development of an integrated control strategy
that would help reduce its morbidity and mortality rates
and maintain cost control is essential. When considering
prevention and treatment strategies for chronic diseases
such as diabetes, Algerian health policymakers should
prioritise health system changes that are structural
(reorganisation of health care services and specialist
training), operational (review of action plan strategies)
and financial (budgetary allocation).
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health experts and medical professionals should promote
the consumption of a balanced, nutritious diet as well as a
regular exercise regimen. It should be noted, however, that
advocating healthier eating might pose financial obstacles
for some households that can only afford the cheaper, less
healthy food options. Despite the gradual improvement
of general living standards, some low-income households
affected by diabetes have difficulty maintaining a diet that
regularly includes pricier foods.
Key policy recommendations are:
1. Train GPs across the country to take a more active
role in the screening of high-risk groups, treatment
and management of type 2 diabetes. This should help
decrease late diagnosis and the frequency of patients
seeking care at higher (and costlier) levels when such
care can instead be delivered at the primary level.
2. Gradually move towards integrated care of NCDs
and increase efforts to improve screening for
complications.
3. Strengthen and integrate existing data collection
systems to allow monitoring of risk-factors, morbidity
and mortality. Ultimately, this will also enable the
evaluation of health programmes and reforms to
tackle not only NCDs but also other conditions.
4. Allocate adequate public resources and devise
government programmes that specifically target
diabetes (particularly type 2). This includes media
campaigns promoting healthier living, including
proper diet and exercise.
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